Finally out of the woods? 5 small and midcap pharma stocks with an upside potential of up to 23%

Pharma as a sector has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, some of the small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

Sometimes a rationale which goes against owning a set of stocks at the start of a bull run, comes in handy in the case of a correction in stock markets. There is one sector where business updates from companies talk in the common lingo. First one is: growth will be muted. Second, margins will be under pressure due to cost inflation and third, competition is increasing in different categories. The sector is FMCG where the narrative is that it is a bad time to buy FMCG stocks. Probably, it is time to take a contrarian call in this sector.

Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a long time. After a long phase of consolidation, in which some companies have implemented change in their business model, are pharma stocks close to breakout ? Stock Reports Plus, powered by Refinitiv, is a comprehensive research report that evaluates five key components of 4,000+ listed stocks - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores.

As the large auto companies make a comeback, even the auto ancillary stocks are coming back on the attention list. We take a look at companies where analysts are projecting further upside in the next 12 months. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.

There are some sectors which are able to face bears in a better way. The reason, the operating matrix of those sectors is such that rising interest rates and other economic headwinds have little impact on their working because they are taking care of a need which is very basic in nature and if spending has to be done on that, it cannot be postponed. Pharmaceutical companies come into that category. This is not to say that there was a phase of almost 7 years that pharma stocks became under-performers. That was a very different reason, most of which have been taken care of. So there is a good chance that this time pharma stock will be able to tackle bears in a much better way.

After inline numbers from TCS and disappointment by infy, it might appear that Q4 earning season for the IT sector has taken a back seat. That might not be the case, as Q4 results will throw a light on how individual companies are managing the situation in a changed environment. Stock Reports Plus, powered by Refinitiv, is a comprehensive research report that evaluates five key components of 4,000+ listed stocks - earnings, fundamentals, relative valuation, risk and price momentum to generate standardized scores.